Abstract:The burden of chronic liver disease is globally increasing at an alarming rate. Chronic liver injury leads to liver inflammation and fibrosis (LF) as critical determinants of long-term outcomes such as cirrhosis, liver cancer, and mortality. LF is a wound-healing process characterized by excessive deposition of extracellular matrix (ECM) proteins due to the activation of hepatic stellate cells (HSCs). In the healthy liver, quiescent HSCs metabolize and store retinoids. Upon fibrogenic activation, quiescent HSCs transdifferentiate into myofibroblasts; lose their vitamin A; upregulate α-smooth muscle actin; and produce proinflammatory soluble mediators, collagens, and inhibitors of ECM degradation. Activated HSCs are the main effector cells during hepatic fibrogenesis. In addition, the accumulation and activation of profibrogenic macrophages in response to hepatocyte death play a critical role in the initiation of HSC activation and survival. The main source of myofibroblasts is resident HSCs. Activated HSCs migrate to the site of active fibrogenesis to initiate the formation of a fibrous scar. Single-cell technologies revealed that quiescent HSCs are highly homogenous, while activated HSCs/myofibroblasts are much more heterogeneous. The complex process of inflammation results from the response of various hepatic cells to hepatocellular death and inflammatory signals related to intrahepatic injury pathways or extrahepatic mediators. Inflammatory processes modulate fibrogenesis by activating HSCs and, in turn, drive immune mechanisms via cytokines and chemokines. Increasing evidence also suggests that cellular stress responses contribute to fibrogenesis. Recent data demonstrated that LF can revert even at advanced stages of cirrhosis if the underlying cause is eliminated, which inhibits the inflammatory and profibrogenic cells. However, despite numerous clinical studies on plausible drug candidates, an approved antifibrotic therapy still remains elusive. This state-of-the-art review presents cellular and molecular mechanisms involved in hepatic fibrogenesis and its resolution, as well as comprehensively discusses the drivers linking liver injury to chronic liver inflammation and LF.

Cellular and molecular mechanisms in the pathogenesis of liver fibrosis: An update

From Basic Science towards Clinical Progress, Focusing on the Central Role of Hepatic Stellate Cells

Cellular and Molecular Mechanisms Underlying Liver Fibrosis Regression

Liver fibrosis and hepatic stellate cells: Etiology, pathological hallmarks and therapeutic targets

Cellular Mechanisms of Liver Fibrosis

Recent perspectives on mechanisms of liver fibrogenesis: microRNA and cell autophagy

Liver Fibrosis Resolution: from Molecular Mechanisms to Therapeutic Opportunities

Cellular basis of hepatic fibrosis and its role in inflammation and cancer

Liver fibrosis: Pathophysiology and clinical implications

An update on the recent advances in antifibrotic therapy

Liver Fibrosis: From Pathogenesis to Novel Therapies

Molecular and cellular mechanisms of liver fibrosis and its regression

Liver fibrosis: mechanisms of immune-mediated liver injury

New Advances in the Molecular Mechanisms Driving Biliary Fibrosis and Emerging Molecular Targets

Molecular therapy for hepatic injury and fibrosis: Where are we?

Intercellular crosstalk of hepatic stellate cells in liver fibrosis: New insights into therapy

Cellular and Molecular Mechanism of Liver Fibrosis: A Critical Insight

TGF-β in Hepatic Stellate Cell Activation and Liver Fibrogenesis—Updated 2019

Targeting Fibrosis: From Molecular Mechanisms to Advanced Therapies